Girl Power 2 Cure and Rett University are excited to share the news! The first ever targeted treatment for Rett Syndrome has been approved by the FDA. Trofinetide (“DAYBUE”) will be available in April 2023. Congratulations and THANK YOU to all of our friends at Acadia Pharmaceuticals!

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

— First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1

— Company expects DAYBUE to be available by the end of April, 2023

— Rare Pediatric Disease Priority Review Voucher granted in connection with approval

— Conference call and webcast to be held March 13, 2023 at 8:30 a.m. Eastern Time

SAN DIEGO–(BUSINESS WIRE)– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome.

This press release features multimedia. View the full release here:

Regards, Kevin